Nephrology - Global Kidney Academy

17-32 of 67

CKD-aP or Something Else? Decoding the Diagnosis
CKD-aP or Something Else? Decoding the Diagnosis
MinuteCE®
CKD-aP or Something Else? Decoding the Diagnosis
James Burton, DM, FRCP; Emilio Sanchez, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
CKD-aP: Beyond the Surface
CKD-aP: Beyond the Surface
MinuteCE®
CKD-aP: Beyond the Surface
Leonie Kraft, MD
1.00 program credit
- Leonie Kraft, MD
1.00 program credit
Quantifying CKD-aP: Tools for Better Care 
Quantifying CKD-aP: Tools for Better Care 
MinuteCE®
Quantifying CKD-aP: Tools for Better Care 
James Burton, DM, FRCP; Emilio Sanchez, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Emilio Sanchez, MD, PhD
1.00 program credit
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
CME/CE
Real-World IgAN: A Case-Based Approach to Maximizing Kidney Preservation
An De Vriese, MD, PhD; Muh Geot Wong, MBBS, PhD
0.25 credits
- An De Vriese, MD, PhD
- Muh Geot Wong, MBBS, PhD
0.25 credits
Future Directions in Managing Hyperkalemia in CKD and HF
Future Directions in Managing Hyperkalemia in CKD and HF
MinuteCE®
Future Directions in Managing Hyperkalemia in CKD and HF
Javed Butler, MD, MPH, MBA; James Burton, DM, FRCP
1.00 program credit
- Javed Butler, MD, MPH, MBA
- James Burton, DM, FRCP
1.00 program credit
Potassium Binders in Practice: Clinical Trial Evidence
Potassium Binders in Practice: Clinical Trial Evidence
MinuteCE®
Potassium Binders in Practice: Clinical Trial Evidence
Ellie Kelepouris, MD, FACP, FAHA; Patrick Rossignol, MD, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
MinuteCE®
Optimizing RAASi/MRA Therapy in Patients with Heart Failure, CKD, and Hyperkalemia: A Microlearning Curriculum Approach
James Burton, DM, FRCP; Javed Butler, MD
1.00 credit 9 episodes
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 credit 9 episodes
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
MinuteCE®
Implementing Potassium Binders: Practical Dosing and Long-Term Follow Up
James Burton, DM, FRCP; Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
- James Burton, DM, FRCP
- Ellie Kelepouris, MD, FACP, FAHA
1.00 program credit
Potassium Binders: Safety Comes First!
Potassium Binders: Safety Comes First!
MinuteCE®
Potassium Binders: Safety Comes First!
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
MinuteCE®
Oral Potassium Binders: A Novel Approach to Curb Hyperkalemia in CKD and HF 
Ellie Kelepouris, MD, FACP, FAHA; Patrick Rossignol, MD, PhD
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
MinuteCE®
Case-Based Application: Optimizing RAASi/MRA Therapy with Potassium Binders
James Burton, DM, FRCP; Patrick Rossignol, MD, PhD
1.00 program credit
- James Burton, DM, FRCP
- Patrick Rossignol, MD, PhD
1.00 program credit
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
MinuteCE®
Optimizing Hyperkalemia Management: Clinical Implications and Risk Assessment
James Burton, DM, FRCP; Javed Butler, MD, MPH, MBA
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD, MPH, MBA
1.00 program credit
Treatment Revolution in IgA Nephropathy
Treatment Revolution in IgA Nephropathy
Nephrology
Treatment Revolution in IgA Nephropathy
Shikha Wadhwani, MD; Dana Rizk, MD
- Shikha Wadhwani, MD
- Dana Rizk, MD
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
MinuteCE®
Guidelines Update: RAASi/MRA Therapy in CKD and HF Management
Ellie Kelepouris, MD, FACP, FAHA; Javed Butler, MD, MPH, MBA
1.00 program credit
- Ellie Kelepouris, MD, FACP, FAHA
- Javed Butler, MD, MPH, MBA
1.00 program credit
The Critical Interplay: CKD, HF, and HyperkaleAmia
The Critical Interplay: CKD, HF, and HyperkaleAmia
MinuteCE®
The Critical Interplay: CKD, HF, and HyperkaleAmia
James Burton, DM, FRCP; Javed Butler, MD
1.00 program credit
- James Burton, DM, FRCP
- Javed Butler, MD
- Ellie Kelepouris, MD, FACP, FAHA
- Patrick Rossignol, MD, PhD
1.00 program credit
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
CME/CE
Optimizing IgAN Care: Achieving Lower Proteinuria Targets With Combination Therapy
Jonathan Barratt, MD, PhD; Sydney Tang, MBBS, MD
0.25 credits
- Jonathan Barratt, MD, PhD
- Sydney Tang, MBBS, MD
0.25 credits

2/5